Last reviewed · How we verify
A Single-centre, Open-label, Three-period Study of the Pharmacokinetic Effect of PA21 on Losartan Potassium in Healthy Male and Female Adults
The purpose of this study is to determine if Losartan potassium is affected by PA21.
Details
| Lead sponsor | Vifor Pharma |
|---|---|
| Phase | Phase 1 |
| Status | COMPLETED |
| Enrolment | 36 |
| Start date | 2011-03 |
| Completion | 2011-06 |
Conditions
- Drug Interaction Potentiation
Interventions
- PA21 and Losartan with Food
- No PA21; Losartan with food
- PA21 with food and Losartan 2 hours later
Primary outcomes
- Effect of PA21 on Losartan potassium — PK assessment on Day 0, 11, 22
To assess the effect, if any, of PA21 on Losartan potassium exposure
Countries
United States